Below are the most recent publications written about "Ranibizumab" by people in Profiles.
-
Shah SM, Boopathiraj N, Starr MR, Dalvin LA, AbouChehade J, Damento G, Garcia MD, Hodge DO, Bakri SJ, Sit AJ, Iezzi R. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2022 11; 243:98-108.
-
Patel SN, Mokhashi N, Peck TJ, Cai LZ, Salabati M, Soares RR, Hinkle J, Chaudhary V, Kuriyan AE, Cohen MN, Hsu J, Garg SJ. Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review. Curr Eye Res. 2022 09; 47(9):1288-1293.
-
Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Regillo CD. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert Opin Biol Ther. 2022 06; 22(6):675-677.
-
Sarohia GS, Nanji K, Khan M, Khalid MF, Rosenberg D, Deonarain DM, Phillips MR, Thabane L, Kaiser PK, Garg SJ, Sivaprasad S, Wykoff CC, Chaudhary V. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022 Sep-Oct; 67(5):1346-1363.
-
Salabati M, Obeid A, Mahmoudzadeh R, Gupta O, Chiang A, Spirn M, Klufas MA, Hsu J. Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022 Aug; 260(8):2509-2516.
-
Nanji K, Sarohia GS, Kennedy K, Ceyhan T, McKechnie T, Phillips M, Devji T, Thabane L, Kaiser P, Sarraf D, Garg SJ, Sivaprasad S, Wykoff CC, Bakri SJ, Sheidow T, Bhandari M, Chaudhary V. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2022 05; 129(5):498-508.
-
Hinkle JW, Hsu J. THE RELATIONSHIP BETWEEN STOPPER POSITION AND INJECTION VOLUME IN RANIBIZUMAB AND AFLIBERCEPT PREFILLED SYRINGES. Retina. 2021 Dec 01; 41(12):2510-2514.
-
Nanji K, Khan M, Khalid MF, Xie JS, Sarohia GS, Phillips M, Thabane L, Garg SJ, Kaiser P, Sivaprasad S, Wykoff CC, Chaudhary V. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022 Sep; 100(6):e1199-e1208.
-
Sharma A, Kumar N, Parachuri N, Karanam D, Kuppermann BD, Bandello F, Regillo CD. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye (Lond). 2022 04; 36(4):679-680.
-
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2022 03; 129(3):295-307.